Concurrent use of nivolumab and radiotherapy for patients with metastatic non-small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab

Checkpoint inhibitors (CPIs), such as nivolumab, have transformed the treatment paradigm for patients with metastatic non-small cell lung cancer (mNSCLC) and metastatic renal cell carcinoma (mRCC). The combination of CPIs and radiotherapy (RT) constitutes a multimodal treatment approach that may wor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansari, Jawaher, Farrag, Ashraf, Ali, Arwa, Abdelgelil, Mai, Murshid, Esam, Alhamad, Abdulaziz, Ali, Muhammad, Ansari, Hidayath, Hussain, Syed, Glaholm, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408674/
https://www.ncbi.nlm.nih.gov/pubmed/34476098
http://dx.doi.org/10.3892/mco.2021.2376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408674/
https://www.ncbi.nlm.nih.gov/pubmed/34476098
http://dx.doi.org/10.3892/mco.2021.2376

Ejemplares similares